acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. The inclusion of medications of the Agreement / in the POS was done to .. partially for the Commission Health Care Regulating in Colombia (CRES). Acuerdo CRES – Deroga El Acuerdo Nuevo POS. Uploaded by. Juan Marulanda · funciones binarias. Uploaded by. Juan Marulanda.
|Published (Last):||8 August 2017|
|PDF File Size:||11.24 Mb|
|ePub File Size:||15.85 Mb|
|Price:||Free* [*Free Regsitration Required]|
Determinar la eficacia del tratamiento hipolipemiante en una muestra de pacientes afiliados al Sistema General de Seguridad Social en Salud de Colombia.
Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: Manuscript received on 14 May Therapy adherence was determined by the degree to which the patient complied with the recommendations recorded by the doctor in the medical record. The characteristics of the population analyzed are shown in Table 1.
Am J Geriatr Pharmacother.
None of the other three groups showed statistically-significant differences between doses of lovastatin. To access other dyslipidemia control medications, the prescribing physician makes a special request through each Empresa Promotora de Salud health services provider, EPS to the Scientific Technical Committee CTC 11, The goal of the ATP III is for the Framingham score to quantify each patient’s “absolute risk of coronary heart disease over 10 years” during routine medical consultation 7, 9.
acuerdo 029 de 2011 cres pdf
Rev Panam Salud Publica. The chi-square test was used to establish associations between variables based on the risk subgroup. According to the results of the present study, the prevalent characteristics of patients in the high cardiovascular risk group with uncontrolled dyslipidemia are two or more of following variables: The above findings support increasing the dose of the lipid-lowering therapy based on clearly defined objectives 16, Dislipidemias; anticolesterolemiantes; enfermedades cardiovasculares; lovastatina; gemfibrozilo; Colombia.
In this study, however, the proportion of patients who claim to have followed the correct treatment was relatively high, which 092 in contrast to the low rate of metabolic control Differences between clinical trial efficacy and real-world effectiveness. Controlled versus uncontrolled dyslipidemic patients.
Issues and evidence for the management of dyslipidaemia in primary care. Primatesta P, Poulter RN.
acuerdo de cres pdf – PDF Files
A statistically-significant association was found between the rate of dyslipidemia control and the following variables: Cre J Cardiovasc Drugs.
Quality and effectiveness of diabetes care for a group of patients in Colombia. Recommendations for the management of dyslipidemia and prevention of cardiovascular disease: In Colombia, the mortality rate due to cardiovascular disease CVD ranks first among women, and second among men.
The mean doses that were used were: Sample size calculation and power analysis: In this study the controlled patients received doses of lovastatin that ce significantly higher than those administered to the uncontrolled patients, but all patients received DDDs lower than the recommended values, as has been reported elsewhere Conversely, it is recommended that insurance companies monitor treatment effectiveness, and even adjust the medication in question, or recommend that the clinician do so The physician must make decisions and modify patient management when achieving the therapeutic goal is difficult 19, Any incomplete record acueedo replaced by the complete record of another randomized patient from the same city and of the same sex and age group.
In the patients comprising risk group 1, It has even been suggested that a suboptimal statin treatment may increase the risk of coronary events Cardiovascular disease and lipids. This 211 be correlated with a lack of knowledge on the part of many physicians around what is a desirable goal based on the patient’s risk and what drug and dose should be prescribed to reach it To determine the effectiveness of lipid-lowering therapy in a sample of patients affiliated with the Sistema General de Seguridad Social en Salud the Colombian health system.
Statistical software was used to select subjects in a stratified random sampling, by city, from among the 8 patients receiving lipid-lowering drugs out of a total of 3.
Additionally, the presence of comorbidities, such as diabetes mellitus, which contribute to cardiovascular risk, should be evaluated for treatment with the drug of choice and at the appropriate dose When life expectancy and income increase among a population, so does the prevalence of noncommunicable diseases NCDssuch as hypertension, obesity, dyslipidemia, and diabetes.
Patient information was reviewed systematically by a physician using a designated data collection form to acuereo the following study variables from the medical records: However, acusrdo the guidelines and the evidence of treatment benefits and safety, numerous studies have acuegdo that a small proportion of dyslipidemic patients regularly use lipid-lowering drugs, and an even smaller percentage of people treated have serum cholesterol levels within the range recommended by international protocols The effectiveness of lipid-lowering therapies was established based on the following groups, defined according to the ATP III goal set and whether it was achieved or not: Additionally, differences between the initial mean: Mean differences were determined by a nonparametric test i.
Most patients in the present study had other risk factors that increased the difficulty of dyslipidemia management and control, especially for asymptomatic diseases, such as hypertension, diabetes, and hypothyroidism; and the use of additional medications for each of these problems results in patients with polypharmacy, as reported by another study Patients also have the legal right to request access to a drug not on the list.
Furthermore, the importance of the starting dose to the overall effectiveness of the therapy has been underscored by a study showing that the percentage reduction in LDL-C levels achieved with the initial dose of statins was strongly correlated with the proportion of patients who maintained their goals at 54 weeks; therefore, it is recommended that therapy start at a dose that should achieve the goal, and if acuereo, be increased significantly to achieve it Acuerdo de Several crres factors were also examined: Eur J Gen Pract.
These cities were selected for convenience because they had relevant and reliable ces available. Under these circumstances, strategies aimed at identifying individuals with dyslipidemia and implementing primary and secondary CVD preventive measures have become health priorities. There was no statistical significance with the following variables: Data collection The quality of the patient records was reviewed by acuuerdo physicians.
The quality of the patient records was reviewed by two physicians.